A former executive with InVentiv Health, Terrell "Terry" Herring has served as president of commercial operations for Mission Pharmacal Company since 2010. In addition to his role with Mission, Terrell "Terry" Herring serves on the advisory board for BioAgilytix, a bioanalytical testing laboratory with locations in North Carolina and Germany. A major area of focus for BioAgilytix is gene therapy and its growing prevalence as a treatment option for diseases such as cancer, Parkinson's, Alzheimer's, and diabetes. Over 200 gene therapy products for cancer were in commercial development as of 2016, while the total number of in-development gene therapy products doubled from 2012 to 2015. The therapy works by using sections of DNA to initiate genetic material into the cells of a patient. The resulting DNA carries a functioning gene which corrects the effects of a particular disease-causing mutation. The adeno-associated virus (AAV) is most commonly used as a carrier to deliver genes to the cells. BioAgilytix's scientists have a wealth of experience analyzing AAV gene therapy options, while the company invests in a variety of platforms used by its customers to facilitate innovation in the field.
0 Comments
Leave a Reply. |
AuthorTerrell Herring began working at Mission Pharmacal Company in 2010, bringing more than 25 years of experience in the pharmaceutical industry to his role as President of Commercial Operations. Archives
February 2018
Categories
All
|